|Memcine Pharmaceuticals, Inc.|
2500 Crosspark Rd., E110
Coralville, IA 52241
<< Back to the listing
Memcine Pharmaceuticals, Inc.
Memcine is developing ImmunoplexTM, the next generation vaccine platform technology aimed at transforming the $26B global vaccine market. ImmunoplexTM is optimized for mucosal delivery, and as such, promises to deliver cost effective needle-free vaccines. Proof-of-concept has been achieved in several preclinical rodent models, including Hepatitis B virus and influenza virus. Early results in a breast cancer murine model suggest that ImmunoplexTM may function as a vaccine immunotherapy in cancer patients. Memcine’s business strategy is to function as a discovery engine and out-license by field and territory for both human and veterinary vaccine applications.